The Medical Letter on Drugs and Therapeutics
Pegaptanib Sodium (Macugen) for Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved pegaptanib sodium (Macugen – Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved treatment for this condition is photodynamic therapy with intravenous verteporfin (Visudyne), which is recommended only for patients with one subtype (predominantly classic) of neovascular AMD.1

THE DISEASE — About 90% of patients with late-stage AMD have the dry or atrophic nonneovascular form; deterioration of central vision may occur slowly. If, however, choroidal neovascularization occurs, there is usually a progressive loss of central vision. Most patients with AMD who have lost vision to the level of legal blindness (best corrected visual acuity of 20/200 or worse in the better-seeing eye) have the neovascular form.

MECHANISM OF ACTION — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegaptanib Sodium (Macugen) for Macular Degeneration
Article code: 1212c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian